DOCSLIB.ORG

Pharmacokinetics of Temocapril and Temocaprilat After 14 Once Daily Oral Doses of Temocapril in Hypertensive Patients with Varying Degrees of Renal Impairment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacokinetics of Temocapril and Temocaprilat After 14 Once Daily Oral Doses of Temocapril in Hypertensive Patients with Varying Degrees of Renal Impairment Br J Clin Pharmacol 1997; 44: 531–536 Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment K. Pu¨chler,1 K. M. Eckl,2 L. Fritsche,3 K. Renneisen,1 H.-H. Neumayer,3 B. Sierakowski,1 A. T. J. Lavrijssen,4 T. Thomsen2 & I. Roots5 1Sankyo Europe GmbH, Duesseldorf, Germany, 2PharmPlanNET Contract Research GmbH, Moenchengladbach, Germany, 3Medizinische Klinik und Poliklinik V (Nephrology), Charite´, Humboldt University, Berlin, Germany, 4Oosterschelde Hospital Goes, The Netherlands, 5Institute of Clinical Pharmacology, University Clinic Charite´, Humboldt University, Berlin, Germany Aims The aim of this study was to determine the potential influence of renal impairment on the pharmacokinetics of temocapril and its pharmacologically active diacid metabolite, temocaprilat. Methods Non-compartmental pharmacokinetics were assessed in four groups of hypertensive patients (n=8 per group, four investigational centres) with normal −1 (creatinine clearance determined via 24 h urine sampling, CLCR, ≥60 ml min ) −1 and impaired renal function (CLCR 40–59, 20–39, <20 ml min ) after 14 once daily oral doses of 10 mg temocapril hydrochloride. Results For temocapril, there were no statistically significant diVerences in median tmax or mean Cmax, AUCSS, tD,Z, CL/F between the four groups. Renal clearance, CL , for temocapril showed a linear decreasing trend with decreasing CL [mean R − CR (s.d.): 32.2 (10.7) to 3.7 (3.0) ml min 1]. Steady-state for temocaprilat was reached on day 5. For temocaprilat, no statistically significant diVerences in mean Cmax or median tmax were detected. With decreasing mean CLCR, mean AUCSS for temocaprilat increased statistically significantly although only 2.4-fold [mean (s.d.): −1 2115 (565) to 4989 (2338) ng ml h] and tD,Z was prolonged [mean (s.d.): 15.2 (1.2) to 20.0 (7.5) h]. CLR for temocaprilat showed a linear decreasing trend with −1 decreasing CLCR [mean (s.d.): 20.2 (4.3) to 3.0 (1.8) ml min ]. Conclusions These results indicate that impaired renal function has only a limited eVect on the pharmacokinetics of temocapril and its active metabolite, temocaprilat. This may be attributed to the dual, i.e. renal and biliary, elimination pathway of the drug. Keywords: temocapril, temocaprilat, ACE inhibitor, renal failure, pharmacokinetics through the alternative route [3, 4]. Because of this, the Introduction drugs can be administered without dosage adjustment to Angiotensin converting enzyme (ACE) inhibitors are a subjects with mild to moderate renal impairment. group of drugs that have assumed an increasingly prominent Temocapril (INN) hydrochloride is (+)-[(2S,6R)-6-[[(S)- role in the management of hypertension; they are eVective 1-(ethoxycarbonyl)-3-phenylpropyl] amino]-5-oxo-2-(2- and well-tolerated and oVer certain advantages in some thienyl)-1,4-thiazepan-4-yl] acetic acid monohydrochloride, subgroups of patients such as diabetic hypertensives. A large a recently developed carboxyl-containing ACE inhibitor number of ACE inhibitors are now available, the great with a dual excretion pathway. It is the ester prodrug of the majority of which are eliminated predominantly through pharmacologically active diacid metabolite temocaprilat. the kidneys [1, 2]. As a result, elimination is aVected by Dose linearity was demonstrated for temocaprilat over the renal impairment in a predictable manner and reductions of dose range of 5–40 mg once daily [Sankyo, data on file]. In doses of ACE inhibitors are generally recommended in this study, we investigated the pharmacokinetics of temocap- patients with reduced renal function [1, 2]. However, some ril and temocaprilat after 14 once daily oral doses of 10 mg of the more recent ACE inhibitors, such as fosinopril and temocapril hydrochloride in hypertensive Caucasian patients spirapril, have dual elimination pathways, both renal and with normal and impaired renal function. The dose studied, hepatic, and when one route of elimination is impaired 10 mg, was selected as it is an eVective dose with respect to there is a compensatory increase in the fractional excretion blood pressure reduction but it is at the lower end of the therapeutic range in Caucasians [Sankyo, data on file]. It Correspondence: Dr Bernd Sierakowski, Sankyo Europe GmbH, Immermannstrasse was expected to be safe and to produce reliable and 45, D-40210 Duesseldorf, Germany. measurable plasma concentrations. © 1997 Blackwell Science Ltd 531 K. Pu¨chler et al. Methods Sample collection and assays On days 5, 8, 11, 12, 13 and 14 predose, blood samples were Patient selection and treatment taken for trough measurements. After the last dose on day Four centres participated, three of which were in Germany 14,bloodsamplesweretakenat0.5,1,1.5,2,3,4,6,8,12, (patients recruited: n=30) and the fourth in the 16, 24, 36, 48, 72, 96 and 120 h. Total urine output was Netherlands (n=2). All subjects provided written informed collected from 0 to 120 h. Blood was drawn into heparinised consent and the study was conducted in accordance with tubes and subjected to centrifugation at 1600 g at 4° Cfor the German Medicines Act, the EU Note for Guidance on 10 min. Plasma and urine samples were stored at −20° C Good Clinical Practice, and the Declaration of Helsinki. until analysis. Plasma and urine concentrations of temocapril Ethics committee approval was obtained before study and temocaprilat were determined using capillary gas chroma- commencement. tography-negative ion chemical ionization mass spectrometry Adult Caucasian subjects with mild to moderate essential (GC-MS) [5]. A deuterated analogue was used as internal hypertension (diastolic blood pressure between 95 and standard and all three compounds were extracted from plasma 114 mmHg, systolic blood pressure 220 mmHg or lower) and urine using a two-stage solid phase procedure with Sep- who had been treated with an ACE inhibitor other than Pak C18 and Sep-Pak silica cartridges. Sequential derivatization fosinopril for at least 3 months were eligible. The degree of carboxylic acid and secondary amino groups was carried of renal impairment was based upon creatinine clearance out using diazomethane and trifluoroacetic acid anhydride, (CLCR) which was assessed by 24 h urine collection on 2 respectively. Negative ion chemical ionization of the deriva- consecutive days during a 3-week screening interval. The tives using methane as reagent gas produced intense high result of the first measurement was set at 100%. The mass fragments ideal for selected ion monitoring. The second had to be in the range 80–120%. If not, a third combination of capillary gas chromatography, derivatization assessment had to be performed which, setting the and monitoring of specific high mass negative ions ensured second at 100%, had to be within the range of 80–120%. no interference from coextracted endogenous plasma compo- The mean of the two relevant results was taken. The nents. Imprecision of the assay did not exceed 3.3% and subjects were grouped according to their CLCR values 11.8% following analysis of CS-622 (temocapril) and as follows: RNH-5139 (temocaprilat) in plasma (8.8% and 3.6%, ≥ −1 Group A CLCR 60 ml min respectively, in urine). Inaccuracy for both analytes did not −1 − + − + Group B CLCR 40–59 ml min exceed 9.8% to 3.9% in plasma ( 9.5% to 12.1% in −1 Group C CLCR 20–39 ml min urine). The lower limit of quantification (LLQ) was < −1 −1 Group D CLCR 20 ml min 0.50 ng ml for both analytes in plasma and urine. Subjects with clinically relevant heart failure, coronary artery disease, valvular defects ( particularly those impeding cardiac Pharmacokinetic evaluation and statistical analysis outflow), renal artery stenosis, only one intact kidney, chronic haemodialysis or any renal condition that might Pharmacokinetic data were analysed by noncompartmental have aVected safety were excluded from the study. Subjects techniques using the TopFit 2.1 software. For peak concen- with clinically significant intercurrent medical conditions tration in plasma, Cmax, and time to reach peak concentration, which might have interfered with the evaluation of tmax, observed values were taken. The apparent terminal pharmacokinetics were also ineligible. elimination rate constant, lZ, was determined by linear All subjects had their ACE inhibitors withdrawn 1 day regression of the terminal phase of the log plasma concen- prior to the start of dosing. Subjects with normal renal tration vs time curve. The terminal half-life, tD,Z,was function were allowed to take between one and three calculated as (ln 2)/lZ. Area under the plasma concentration additional antihypertensive drugs including diuretics (e.g. vs time curve was calculated by the linear-logarithmic frusemide, calcium-antagonists, and vasodilative drugs such trapezoidal rule up to 24 and 120 h for AUCSS and as clonidine or dihydrallazine), oral contraceptives, paraceta- AUC(0,120 h), respectively, and, for AUC, up to the last mol or aspirin and, if necessary, the previously used ACE time at which the concentration was equal to or above the inhibitor after the 48 h postadministration sample. Those LLQ, AUC(0,t), and extrapolated to infinity by dividing the with impaired renal function were allowed to take drugs as plasma concentration at time t by lZ and adding this value to above plus insulin, calcium carbonate, cholecalciferol, and AUC(0,t). The apparent total plasma clearance, CL/F,was vitamin preparations. calculated by dividing the dose (10 mg) by the AUCSS for Subjects took temocapril hydrochloride (film-coated temocapril. The renal clearance from plasma, CLR,was tablets supplied by Sankyo Pharma GmbH, Munich, calculated by dividing urinary recovery of temocapril, Ae, Germany) orally at a dose of 10 mg once daily for 14 days. and temocaprilat, Ae(m), by the related AUC(0,120 h). Medication was taken with 200 ml water after a continental The temocapril and temocaprilat trough plasma concen- breakfast between 07.00 h and 09.00 h for the first 13 days trations of days 5, 8, 11, 12 and 13 were analysed by and, after fasting overnight for at least 10 h, on day 14 (last regression analysis.
Load more

Recommended publications
  • Effects of Monotherapy of Temocapril Or Candesartan with Dose Increments Or Combination Therapy with Both Drugs on the Suppression of Diabetic Nephropathy
    325 Hypertens Res Vol.30 (2007) No.4 p.325-334 Original Article Effects of Monotherapy of Temocapril or Candesartan with Dose Increments or Combination Therapy with Both Drugs on the Suppression of Diabetic Nephropathy Susumu OGAWA1), Kazuhisa TAKEUCHI1), Takefumi MORI1), Kazuhiro NAKO1), Yoshitaka TSUBONO2),3), and Sadayoshi ITO1) We examined the effects of increasing the recommended initial doses of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), or of switching to combination therapy with both drugs, on diabetic nephropathy. Hypertensive type 2 diabetic patients with urinary albumin excretion (ACR) between 100 and 300 mg/g creatinine (Cre) were assigned to the following five groups in which an antihy- pertensive drug was administered at a recommended initial dose for 48 weeks, and then either the dose was doubled or an additional drugs was added to regimen for the following 48 weeks: N, nifedipine-CR (N) 20 mg/day (initial dose); T, ACEI temocapril (T) 2 mg/day; C, ARB candesartan (C) 4 mg/day; T+C, T first and then addition of C; C+T, C first and then addition of C. ACR decreased in the T (n=34), C (n=40), T+C (n=37) and C+T (n=35) groups, but not in the N group (n=18). However, the anti-proteinuric effect was less in the T than in the C, T+C or C+T groups, while no differences existed among the latter three. In each group, there were significant linear relationships between attained BP and ACR; however, the regression lines were shifted toward lower ACR level in the renin-angiotensin system–inhibition groups compared with the N group.
    [Show full text]
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy
    929 Hypertens Res Vol.30 (2007) No.10 p.929-935 Original Article Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy Hirohiko ABE1), Shinya MINATOGUCHI1), Hiroshige OHASHI1), Ichijiro MURATA1), Taro MINAGAWA1), Toshio OKUMA1), Hitomi YOKOYAMA1), Hisato TAKATSU1), Tadatake TAKAYA1), Toshihiko NAGANO1), Yukio OSUMI1), Masao KAKAMI1), Tatsuo TSUKAMOTO1), Tsutomu TANAKA1), Kunihiko HIEI1), and Hisayoshi FUJIWARA1) Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are fre- quently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albumin- uria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was inef- fective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. Dur- ing the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively.
    [Show full text]
  • Combination Therapy with Olmesartan and Temocapril Ameliorates Renal Damage and Upregulates the Klotho Gene in 5/6 Nephrectomized Spontaneously Hypertensive Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Tottori University Research Result Repository Yonago Acta medica 2009;52:27–35 Combination Therapy with Olmesartan and Temocapril Ameliorates Renal Damage and Upregulates the klotho Gene in 5/6 Nephrectomized Spontaneously Hypertensive Rats Satoko Maeta, Chishio Munemura, Takeaki Fukui, Chihiro Ishida and Yoshikazu Murawaki Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504 Japan Recent studies suggest that chronic kidney disease may induce cardiovascular disease through oxidative stress, and that the aging suppressor gene klotho reduces oxidative stress in the kidney. In this study, we examined the changes in klotho gene expression, and the renoprotective effects of olmesartan (OLM), angiotensin II receptor blocker (ARB) alone or in combination with temocapril (TEM), angiotensin-converting enzyme inhibitor (ACEI) in 5/6-nephrectomized (5/6-Nx) spontaneously hypertensive rats. Male 5/6-Nx spontane- ously hypertensive rats were randomly assigned to 5 groups as follows: control group; 5/6-Nx group, 5/6-Nx rats; low OLM group, 5/6-Nx rats administered low-dose OLM (3 mg/kg/day); high OLM group, 5/6-Nx rats administered high-dose OLM (10 mg/kg/day); OLM+TEM group, 5/6-Nx rats administered high-dose OLM and TEM (10 mg/kg/day each). These drugs were administered for 12 weeks. Systolic blood pressure, glomerular sclerosis and transforming growth factor beta 1 mRNA in high OLM and OLM+TEM groups were significantly lower than that in the 5/6-Nx group.
    [Show full text]
  • “Captopril” [Mesh
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart PubMed: 1. (“dose comparison” OR “dose” OR “low dose” OR “high dose” OR “dosage*”) 2. (“captopril” [mesh] OR “Benazepril” OR “Enalapril” [mesh] OR “Enalapril” OR “Cilazapril” [mesh] OR “Cilazapril” OR “Delapril” OR “Imidapril” OR “Lisinopril” [mesh] OR “Lisinopril” OR “Moexipril” OR “Perindopril” [mesh] OR “Perindopril” OR “Quinapril” OR “Ramipril” [mesh] “Ramipril” OR “Spirapril” OR “Temocapril” OR “Trandolapril” OR “Zofenopril” OR “Enalaprilat” [mesh] OR “Enalaprilat” OR “Fosinopril” [mesh] OR “Fosinopril” OR “Teprotide” [mesh] OR “Teprotide” OR “Angiotensin-Converting Enzyme Inhibitors” [mesh] OR “Angiotensin-Converting Enzyme Inhibitors” OR “Angiotensin Converting Enzyme Inhibitors” OR “Inhibitors, Kininase II” OR “Kininase II Antagonists” OR “Kininase II Inhibitors” OR “Angiotensin I-Converting Enzyme Inhibitors” OR “Angiotensin I Converting Enzyme Inhibitors” OR “Antagonists, Angiotensin- Converting Enzyme” OR “Antagonists, Angiotensin Converting Enzyme” OR “Antagonists, Kininase II” OR “Inhibitors, ACE” OR “ACE Inhibitors” OR “Inhibitors, Angiotensin-Converting Enzyme” OR “Enzyme Inhibitors, Angiotensin-Converting” OR “Inhibitors, Angiotensin Converting Enzyme” OR “Angiotensin-Converting Enzyme Antagonists” OR “Angiotensin Converting Enzyme Antagonists” OR “Enzyme Antagonists, Angiotensin-Converting”) 3. (“Heart failure” [mesh] OR “heart failure” OR “Cardiac Failure” OR “Heart Decompensation” OR “Decompensation, Heart” OR “Heart Failure, Right-Sided” OR “Heart Failure, Right Sided” OR “Right-Sided Heart Failure” OR “Right Sided Heart Failure” OR “Myocardial Failure” OR “Congestive Heart Failure” OR “Heart Failure, Congestive” OR “Heart Failure, Left-Sided” OR “Heart Failure, Left Sided” OR “Left-Sided Heart Failure” OR “Left Sided Heart Failure” OR “chronic heart failure” OR "chronic heart" OR (CHF)) 4.
    [Show full text]
  • Quantify Chronic Kidney Disease Clinical Outcomes Database
    Quantify Chronic Kidney Disease Clinical Outcomes Database Summary Information The current version of the database includes clinical safety and efficacy information on treatment options currently approved or in development for Chronic Kidney Disease (CKD) progression Features and Benefits in patients with Type 2 Diabetes Mellitus (T2DM) and overt Key Features albuminuria/proteinuria, as well as patients with IGA nephropathy. • Comprehensive: includes information for marketed drugs; data sources include journal publications, conference posters, Table 1. Summary information regulatory reviews, etc Parameter Description • Ease of tracking: all clinical trial publications are listed in a format Excel or KEEP format indications iga nephropathy, diabetic nephropathy, separate source database and linked to unique clinical trial names nephropathy, proteinuria • Flexibility: the database design allows for quick updates as references 99 well as expansions to include additional indications/drugs/ trials 88 endpoints/trials trial.arms 214 patients 17,364 • Model-friendliness: designed and reviewed by experienced data.rows 5,456 modelers to ensure highest quality and usability for modeling compounds aliskiren, amlodipine, atenolol, atrasentan, and simulation to support drug development strategies avosentan, azathioprine, azelnidipine, bardoxolone methyl, benazepril, canagliflozin, • Customizability: can be augmented with clinical trial data candesartan cilexetil, captopril, chlorthalidone, proprietary to the client (this information goes into a separate
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • Effects of Long-Acting ACE Inhibitor (Temocapril) and Long-Acting Ca Channel Blocker (Amlodipine) on 24-H Ambulatory BP in Elderly Hypertensive Patients
    Journal of Human Hypertension (2001) 15, 643–648 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients K Eguchi1,2, K Kario2 and K Shimada2 1Department of Internal Medicine, Nishiarita Kyoritu Hospital, Saga, Japan; 2Department of Cardiology, Jichi Medical School, Tochigi, Japan In a prospective randomised cross-over study, we com- ferences in the office, 24-h or daytime BPs between the pared the effects of ACE inhibitor temocapril and cal- two groups (dippers and non-dippers). Though the cium channel blocker (CCB) amlodipine on ambulatory office BPs and daytime BPs were successfully con- blood pressure in 59 asymptomatic elderly hypertensive trolled to the same levels with both treatments and in patients (mean age 69 years). This study was performed both dipping groups, the antihypertensive effects were in a cross-over fashion after a 2-week placebo period stronger with the CCB than with the ACE inhibitor in the and 4 to 8 weeks each of treatment with temocapril and night time and morning, especially in non-dippers. We amlodipine. Of those 59 hypertensive patients, three conclude that even though office BPs were controlled patients with side effects and 10 patients whose office successfully to almost the same levels, there is a possi- BPs did not achieve the target BPs were excluded, and bility that these long-acting drugs have differential anti- the remaining 46 were analysed in this study: they con- hypertensive effects on night time and morning BPs sisted of 30 dippers, with a night time reduction in sys- among hypertensive patients with different night time tolic BP (SBP) у10% and 16 non-dippers, with reduction BP dipping statuses.
    [Show full text]
  • Comparative Proteinuria Management of Different Angiotensin-Converting Enzyme Inhibitors Or Angiotensin Receptor Blockers for No
    Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis Huizhen Ye*, Zhihao Huo*, Peiyi Ye, Guanqing Xiao, Zhe Zhang, Chao Xie and Yaozhong Kong Nephrology Department, The First People's Foshan Hospital, Foshan, Guangdong, China * These authors contributed equally to this work. ABSTRACT Background. Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are blood pressure-lowering agents, but they are also being used to control proteinuria in early chronic kidney disease (CKD) patients. However, clinically, some patients present merely proteinuria without hypertension. No guidelines pointed out how to select treatments for proteinuria in normotensive patients. Thus, we conducted a Bayesian network analysis to evaluate the relative effects of different kinds of ACEI or ARB or their combination on proteinuria and blood pressure reduction. Methods. The protocol was registered in PROSPERO with ID CRD42017073721. A comprehensive literature database query was carried out systematically according to PICOS strategies. The primary outcome was reduction in proteinuria, and the secondary outcomes were eGFR reduction and blood pressure reduction. Random- effects pairwise and Bayesian network meta-analyses were used to estimate the effect of different regimens. Results. A total of 14 RCTs with 1,098 patients were included in the analysis. All Submitted 2 September 2019 treatment strategies of ACEI, ARB or their combination had significantly greater efficacy Accepted 16 January 2020 Published 12 March 2020 in reducing proteinuria than placebo in normotensive CKD patients. The combination therapy of olmesartan+temocapril had the highest probability (22%) of being the most Corresponding author Yaozhong Kong, [email protected] effective treatment to reduce proteinuria in normotensive CKD patients.
    [Show full text]
  • Telmisartan Versus Angiotension-Converting
    Journal of Human Hypertension (2009) 23, 339–349 & 2009 Macmillan Publishers Limited All rights reserved 0950-9240/09 $32.00 www.nature.com/jhh ORIGINAL ARTICLE Telmisartan versus angiotension- converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials Z Zou1,3, G-L Xi2,3, H-B Yuan1, Q-F Zhu1 and X-Y Shi1 1Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China and 2Center for New Drug Evaluation, Institute of Basic Medical Science, Second Military Medical University, Shanghai, People’s Republic of China Telmisartan and angiotensin-converting enzyme inhibi- 0.33–2.62). Telmisartan also showed a greater DBP tors (ACEIs) are both effective and widely used response rate than enalapril (relative risk (RR) 1.15, antihypertensive drugs targeting renin–angiotensin– 95% CI 1.05–1.26), ramipril (RR 1.34, 95% CI 1.11–1.61) aldosterone system. The study aimed to estimate the and perindopril (RR 1.22, 95% CI 1.05–1.41). There was efficacy and tolerability of telmisartan in comparison no statistical difference in DBP reduction or therapeutic with different ACEIs as monotherapy in the treatment of response rate between telmisartan and lisinopril (WMD hypertension. Cochrane Central Register of Controlled À0.30, 95% CI À0.65 to 0.05; RR 0.99, 95% CI 0.80–1.23, Trials, PubMed and Embase were searched for relevant respectively). Telmisartan had fewer drug-related studies. A meta-analysis of all randomized controlled adverse events than enalapril (RR 0.57, 95% CI 0.44–0.74), trials fulfilling the predefined criteria was performed.
    [Show full text]
  • Effect of Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker on the Patients with Sepsis
    ORIGINAL ARTICLE Korean J Intern Med 2021;36:371-381 https://doi.org/10.3904/kjim.2019.262 Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis Hyun Woo Lee1,*,†, Jae Kyung Suh2,*, Eunjin Jang3, and Sang-Min Lee1 1Division of Pulmonary and Critical Background/Aims: Inhibitors of the renin-angiotensin system, angiotensin-con- Care Medicine, Department of verting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), Internal Medicine, Seoul National University Hospital, Seoul; 2National reportedly have anti-inflammatory effects. This study assessed the association of Evidence-Based Healthcare prior use of ACE inhibitors and ARBs with sepsis-related clinical outcomes. Collaborating Agency, Seoul; 3 Methods: A population-based observational study was conducted using the Department of Information Statistics, Andong National University, Andong, Health Insurance Review and Assessment Service claims data. Among the adult Korea patients hospitalized with new onset of sepsis in 2012, patients who took ARBs or ACE inhibitors at least 30 days prior to hospitalization were analyzed. Generalized linear models and logistic regression were used to examine the relation between the prior use of medication and clinical outcomes, such as in-hospital mortality, mechanical ventilation, and length of stay. Results: Of a total of 27,628 patients who were hospitalized for sepsis, the ACE in- Received : August 8, 2019 hibitor, ARB, and non-user groups included 1,214 (4.4%), 3,951 (14.4%), and 22,463 Revised : October 19, 2019 (82.1%) patients, respectively. As the patients in the ACE inhibitor and ARB groups Accepted : November 25, 2019 had several comorbid conditions, higher rates of intensive care unit admission, Correspondence to hemodialysis, and mechanical ventilation were observed.
    [Show full text]